LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental
17.02.2022 - LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) - COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release .
Investegate announcements from COMPASS Pathways, Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK - 4 January 2022